China approves Zai Lab’s Cobenfy, first new Schizophrenia mechanism in decades
Share
Zai Lab Limited (NASDAQ:ZLAB) received marketing authorization from China’s National Medical Products Administration (NMPA) for Cobenfy, a groundbreaking treatment for schizophrenia in adults.
